New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Psyence Biomedical Ltd.

PBM

Healthcare Biotechnology

2.97 0.11 +3.85%

After hours trading: 3.01, up 1.35%, last trade Fri 4:09pm Eastern.

Market cap
$10.9M
P/E
0.1×
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
—
Net debt / EBITDA
1.2×
Payout ratio
—

Ratios over time FY23 to FY26

Returns on capital

ROIC was −41.2% in FY26, against a low of −415.6% in FY25. ROE, at −58.6%, is far above it because equity is small against the capital the business uses.

ROEROIC
FY23FY24FY25FY26
ROE−54.7%149.5%−47.6%−58.6%
ROIC0.0%0.0%−415.6%−41.2%

Debt

Net debt is 1.20× a year’s EBITDA. Debt is 0.00× equity.

Debt / equityNet debt / EBITDA
FY20FY21FY23FY24FY25FY26
Debt / equity0.0×0.0×0.0×0.0×0.0×0.0×
Net debt / EBITDA1.9×0.1×0.3×0.3×1.7×1.2×
Mar '26 Mar '25 Mar '24 Dec '23 Jan '22 Jan '21 Dec '17
Current Ratio
14.62 11.04 0.09 0.09 0.08 14.17 —
Net Debt/EBITDA
1.20 1.69 0.28 0.28 0.10 1.94 —
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 —
ROE
(58.62%) (47.61%) 149.52% (54.66%) 3.33% — —
ROA
(55.75%) 23.95% (4,518.56%) (39.34%) 3.11% 6.42% —
ROIC
(41.24%) (415.57%) 0.00% 0.00% — — —
Return on Tangible Assets
(81.67%) 16.93% 466.25% 466.25% (61.34%) 909.94% —
Free Cash Flow per Share
(14.74) (121.17) (1,735.94) — (0.02) (0.03) —
Book value per Share
30.68 217.54 (6,454.41) (1.32) 7.49 7.24 —
Free Cash Flow
(8.14) (3.74) (2.95) — (0.52) (0.84) —
Other line items

Show all line items

Columns are period end dates